| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-09-14 | dusquetide | preclinical | Soligenix (USA - NJ) | ||
| 2017-09-13 | LN-145 | recurrent, metastatic or persistent cervical carcinoma | 2 | Iovance Biotherapeutics (USA - CA) | Cancer - Oncology |
| 2017-09-12 | ACI-24 | Down syndrome | 1b | AC Immune (Switzerland) University of California San Diego (USA - CA) | Genetic diseases |
| 2017-09-12 | evobrutinib - M2951 | rheumatoid arthritis | 2b | Merck KGaA (Germany) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-09-11 | DS-8201a | advanced/unresectable or metastatic breast cancer, gastric or gastroesophageal junction adenocarcinoma, or other solid tumors that is/are refractory to or intolerable with standard treatment or for which no standard treatment is available | 1 | Daiichi Sankyo (Japan) | Cancer - Oncology |
| 2017-09-11 | TSR-042 | advanced solid tumors | 1 | Tesaro (US - MA) | Cancer - Oncology |
| 2017-09-11 | upadacitinib (ABT-494) | rheumatoid arthritis | 2 | Abbvie (USA - IL) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-09-11 | combination of dabrafenib and trametinib | metastatic melanoma with BRAF V600 mutations |
3 | GSK (UK) | Cancer - Oncology |
| 2017-09-11 | Livatag® (doxorubicin Transdrug®) | hepatocellular carcinoma, primary liver cancer | 3 | BioAlliance Pharma, now Onxeo (France) | Cancer - Oncology |
| 2017-09-11 | ABX464 | HIV/Aids | 2a | Abivax (France) | Infectious diseases |
| 2017-09-11 | niraparib (MK-4827) | ovarian cancer | 3 | Tesaro (US - MA) ENGOT (European Network of Gynaecological Oncology Trial Groups) NSGO (Nordic Society of Gynaecological Oncology) | Cancer - Oncology |
| 2017-09-11 | Keytruda® (pembrolizumab) | recurrent or metastatic head and neck squamous cell carcinoma | 3 | Merck&Co (USA - NJ) | Cancer - Oncology |
| 2017-09-11 | TG4010 and nivolumab | advanced non-squamous non-small cell lung cancer (NSCLC) | 2 | Transgene (France) | Cancer - Oncology |
| 2017-09-11 | TG4010 and nivolumab | advanced non-squamous non-small cell lung cancer (NSCLC) | 2 | Transgene (France) | Cancer - Oncology |
| 2017-09-11 | niraparib and bevacizumab | platinum-sensitive epithelial ovarian cancer | 2 | Nordic Society for Gynaecologic Oncology | Cancer - Oncology |
| 2017-09-11 | niraparib in combination with pembrolizumab | triple-negative breast cancer orovarian Cancer | 1-2 | Tesaro (US - MA) | Cancer - Oncology |
| 2017-09-11 | burosumab - KRN23 (UX023) | tumor-induced osteomalacia (TIO) | 2 | Ultragenyx Pharmaceutical (USA - CA) | Rare diseases |
| 2017-09-10 | BLU-554 | advanced hepatocellular carcinoma (HCC) | 1 | Blueprint Medicines (USA - MA) | Cancer - Oncology |
| 2017-09-10 | Eladynos®/Tymlos® (abaloparatide) | postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy | 3 | Radius Health (USA - MA) | Bone diseases |
| 2017-09-10 | Cyramza® (ramucirumab) | urothelial carcinoma | 3 | Eli Lilly (USA - IN) | Cancer - Oncology |
